Matthew T. Ballo, MD, FACR - Readying the Modern Radiation Oncology Practice for Incorporation of a Fourth Modality in Cancer Treatment: Understanding the Science, Evidence & Clinical Application Acro

Go online to PeerView.com/APQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While much of cancer therapy development focuses on systemic drugs and the mitigation of associated adverse events, new avenues utilizing innovative multimodal solutions have demonstrated the benefit of efficacy with minimal toxicity in solid tumors. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies have emerged and entered into the management paradigms of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM) and are set to evolve the standards of care for patients with other solid tumors as well. In this activity, based on a recent live symposium held in Chicago, Illinois, radiation and medical oncology experts review cutting-edge advancements in cancer technology, such as TTFields, and offer insight and case discussions illustrating the appropriate integration of innovative solutions into cancer management. Moreover, the expert panel reviews multimodal strategies in GBM and examines the impact of novel treatment modalities available for MPM, as well as new approaches that are emerging for other tumors, including thoracic, pancreatic, liver, and ovarian cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for the use of novel technologies, such as tumor treating fields (TTFields), as a cancer therapeutic strategy, Assess the latest safety and efficacy evidence on innovative strategies available for the therapeutic management of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Cite the latest evidence and ongoing clinical trials on novel treatments, including combining TTFields or radiotherapy with systemic therapy, in multiple tumor types, such as lung, pancreatic, liver, and ovarian cancers, across different treatment settings, Plan strategies to integrate novel technologies into the therapeutic management of patients with cancer, including through enrollment in clinical trials